Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.95 +0.09 (+0.18%)
Streaming Delayed Price Updated: 3:06 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
37 38 Next >
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain
The company reported more than 40% growth for Dupixent in the second quarter. 
Via Investor's Business Daily
Sanofi Raises Annual Guidance On Upbeat Q2 Performance
 
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
Earnings Outlook For Sanofi
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
 
Via Benzinga
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
 
Via Benzinga
Daily Stock Analysis: Sanofi S.A.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris. 
Via Talk Markets
Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients
 
Via Benzinga
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold
The company was testing the drug in multiple sclerosis and myasthenia gravis. 
Via Investor's Business Daily
Earnings Scheduled For July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
Why Sanofi Shares Are Falling Today
 
Via Benzinga
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies. 
Via Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
Analyzing Sanofi's Short Interest
Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of... 
Via Benzinga
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis. 
Via InvestorPlace
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
 
Via Benzinga
Sanofi Offloads 17 Products To Neuraxpharm
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.  
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
 
Via Benzinga
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
This New York-Based Digital Therapeutics Company Looks To Disrupt a $475 Billion Market
As the global coronavirus pandemic forced people to keep their distance from one another, there has been an increase in the adoption of digital health solutions among healthcare professionals and... 
Via Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
How Is The Market Feeling About Sanofi?
Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.